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ABSTRACT
This study examined whether dietary supplementation can be used to protect against isch-
emic stroke. Two groups of adult male Sprague-Dawley rats initially received NT-020, a pro-
prietary formulation of blueberry, green tea, Vitamin D3, and carnosine (n   8), or vehicle
(n   7). Dosing for NT-020 and vehicle consisted of daily oral administration (using a gav-
age) over a 2-week period. On day 14 following the last drug treatment, all animals under-
went the stroke surgery using the transient 1-hour suture occlusion of middle cerebral artery
(MCAo). To reveal the functional effects of NT-020, animals were subjected to established
behavioral tests just prior to stroke surgery and again on day 14 post-stroke. ANOVA revealed
significant treatment effects (p   0.05), characterized by reductions of 11.8% and 24.4% in mo-
tor asymmetry and neurologic dysfunction, respectively, in NT-020-treated stroke animals
compared to vehicle-treated stroke animals. Evaluation of cerebral infarction revealed a sig-
nificant 75% decrement in mean glial scar area in the ischemic striatum of NT-020-treated
stroke animals compared to that of vehicle-treated stroke animals (p   0.0005). Quantitative
analysis of subventricular zone’s cell proliferative activity revealed at least a one-fold incre-
ment in the number of BrdU-positive cells in the NT-020-treated stroke brains compared to
vehicle-treated stroke brains (p   0.0005). Similarly, quantitative analysis of BrdU labeling in
the ischemic striatal penumbra revealed at least a three-fold increase in the number of BrdU-
positive cells in the NT-020-treated stroke brains compared to vehicle-treated stroke brains
(p   0.0001). In addition, widespread double labeling of cells with BrdU and doublecortin
was detected in NT-020-treated stroke brains (intact side 17% and ischemic side 75%), which
was significantly higher than those seen in vehicle-treated stroke brains (intact side 5% and
ischemic side 13%) (p   0.05). In contrast, only a small number of cells in NT-020-treated stroke
brains double labeled with BrdU and GFAP (intact side 1% and ischemic side 2%), which was
significantly lower than those vehicle-treated stroke brains (intact side 18% and ischemic side
35%) (p   0.0001). Endogenous neurogenic factors were also significantly upregulated in the
ischemic brains of NT-020-treated stroke animals. These data demonstrate the remarkable
neuroprotective effects of NT-020 when given prior to stroke, possibly acting via its neuro-
genic potential.
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S
TROKE IS THE THIRD LEADING CAUSE OF DEATH
and the leading cause for disability in the
United States with approximately two out of
every 1000 adult Americans experiencing their
first stroke in any given year. The current ther-
apy for stroke is limited to tissue plasminogen
activator (tPA). The numbers of affected indi-
viduals, the costs necessary to facilitate their
care and rehabilitation, coupled with the lack
of therapies, warrant significant research ef-
forts to alleviate the suffering of stroke victims.
Accumulating evidence over the past decade
indicates that neurogenesis occurs in the adult
mammalian CNS.1 Regenerative medicine has
emerged as a new scientific field advancing
stem cell therapy for treating brain disorders,
with emphasis on either transplanting exoge-
nous stem cells or amplifying endogenous stem
cells via neurogenesis.2,3 In this study, we ex-
plored how diet supplementation affects neu-
rogenesis in adult stroke rats. Relevant diet ma-
nipulation paradigms have been examined in
the recent past, including diet restriction and
fasting, which have been reported to influence
neurogenesis.4–9 In particular, caloric restric-
tion has been shown to increase neurogenesis
in CNS neurogenic sites, which coincided with
amelioration of stroke-induced behavioral and
histological deficits.5,10,11 Careful examination
of the diet restriction regimen reveals that the
overarching principle of such neurogenesis-en-
hancing strategy is to eliminate the unwanted
calories. We posit here that an equally robust
neuroprotective approach might be achieved
by pursuing the reverse paradigm of increas-
ing the nutritive diet that should also render a
therapeutically potent neurogenesis. Hence,
we put forward the unifying concept of diet
manipulation that encompasses either elimi-
nating the detrimental calories or enhancing
the nutritive diet in order to achieve neuro-
protection. Our hypothesis of neurogenesis-in-
duced neuroprotection complements the con-
cept suppression of oxidative stress as an
equally efficacious benefit rendered by a nutri-
tive diet including blueberries,12,13 green
tea,14,15 vitamin D3,16,17 and carnosine,18,19 con-
sidering that these plant extracts are rich in po-
tent antioxidants and chelating polyphenol
compounds.20 The proposed study will eluci-
date the biological effects of supplementation
of nutritive diet extracts/compounds, referred
to herein as NT-020, on promoting neurogene-
sis and exerting functional benefits in a stroke
model.
EXPERIMENTAL RESEARCH 
DESIGN AND METHODS
Subjects
Adult male Sprague-Dawley rats (Harlan,
Madison, WI) weighing about 250 g served as
subjects. Animals had free access to food and
water before and after surgical procedures. All
experimental procedures followed the Augusta
NIH guidelines for the use of animals in re-
search. Surgical procedures were conducted
under aseptic conditions, and every effort was
made to minimize animal suffering and to re-
duce the number of animals used.
Drug dosing
Animals were randomly assigned to initially
receive NT-020 (n   8) or vehicle (n   7). In us-
ing NT-020, the highest dosages of the compo-
nents determined to promote the greatest
amount of cell proliferation in the in vitro cell
studies21 were adjusted accordingly for in vivo
administration. NT-020 is a proprietary formu-
lation of blueberry, green tea, Vitamin D3, and
carnosine based upon previously published re-
search.17,21 However, in this previous study21
a higher level of Vitamin D3 was included in
the formulation. The present dosing for NT-020
and vehicle consisted of daily oral administra-
tion (using a gavage) over a 2-week pre-stroke
period. As indicated by Wang and colleagues,22
such a dosing regimen of pre-stroke diet sup-
plementation is within the therapeutic range to
promote neuroprotection; however the amount
of individual ingredients used in the present
study is 20 times less than that in the previous
studies.21,22
Stroke surgery
On day 14, following the last drug treatment,
all animals underwent stroke surgery using the
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cerebral artery (MCAo). This MCAo stroke
model followed the procedures described in
our previous studies.23–26
Behavioral testing
To reveal the functional effects of NT-020, an-
imals were subjected to established behavioral
tests just prior to stroke surgery and again on
day 14 post-stroke. Behavioral tests included
Bederson test and elevated body swing test
(EBST), which are both sensitive to stroke-in-
duced motor and neurological deficits respec-
tively. The Bederson test is conducted following
the procedures previously described.23,24 Neu-
rologic score for each rat is obtained using 4
tests which include: (1) observation of sponta-
neous ipsilateral circling, graded from 0 (no cir-
cling) to 3 (continuous circling); (2) contralat-
eral hindlimb retraction, which measures the
ability of the animal to replace the hindlimb af-
ter it is displaced laterally by 2 to 3 cm, graded
from 0 (immediate replacement) to 3 (replace-
ment after minutes or no replacement); (3)
beam walking ability, graded 0 for a rat that
readily traverses a 2.4-cm-wide, 80-cm-long
beam to 3 for a rat unable to stay on the beam
for 10 s; and (4) bilateral forepaw grasp, which
measures the ability to hold onto a 2-mm-di-
ameter steel rod, graded 0 for a rat with nor-
mal forepaw grasping behavior to 3 for a rat
unable to grasp with the forepaws. The scores
from all 4 tests are added and the average cal-
culated to give a neurologic deficit score (max-
imum possible score, 3).
The EBST involves handling the animal by
its tail and recording the direction of the
swings. The animal is gently picked up at the
base of the tail and elevated until the animal’s
nose is at a height of 2 in (5 cm) above the sur-
face. The direction of the swing, either left or
right, is counted once the animal’s head moves
sideways approximately 10 degrees from the
midline position of the body. After a single
swing, the animal is placed back in the Plexi-
glas box and allowed to move freely for 30 s
prior to retesting. These steps are repeated 20
times for each animal. Normally, intact rats
display a 50% swing bias, that is, the same
number of swings to the left and to the right.
A 75% swing bias would indicate 15 swings in
one direction and 5 in the other during 20 tri-
als. We have previously utilized the EBST, and
noted that MCAo stroke animals display  75%
bias swing activity as early as the day of stroke
surgery (i.e., after recovery from anesthesia),
and such motor asymmetry is stable for up to
6 months.27–29 All tests were conducted by two
investigators blinded to the treatment condi-
tion.
Cerebral infarction analysis
Following the behavioral testing at day 14
post-stroke, all animals were euthanized for
evaluation of cerebral infarction using the glial
fibrillary acidic protein (GFAP) immunostain-
ing.30 This routine GFAP assay reveals the ex-
tent of glial scar, which closely approximates
the cerebral damage in stroke. Although triph-
enyltetrazolium chloride (TTC) is more rou-
tinely used to reveal cerebral infarction, such
TTC assay is only sensitive when performed
within 7 days post-stroke. Using an NIH imag-
ing system, the glial scar was calculated by cap-
turing images using AxioPhot (Carl Zeiss,
Thornwood, NY) at 1.6-fold magnification. The
damaged area was selected according to the
morphology of the cells based on glial infiltra-
tion, which clearly delineated the ischemic core
from the ischemic penumbra.30 The mean area
of damage of 5–6 sections per coronal slice was
calculated using the following formula: C  
D/(A   B) to reveal the total infarct area per
brain (see Fig. 2A).
Cell proliferation assay
To determine whether the NT-020-induced
cell proliferation seen in vitro also occurs in
vivo, which could serve as the mechanistic ex-
planation for the observed behavioral and his-
tological protection, we examined the BrdU
staining in discrete regions of the stroke brain.
Alternate brain sections obtained from the
same NT-020- or vehicle-treated stroke animals
above were processed for BrdU immunostain-
ing (50 mg/kg, i.p. every 8 h during days 10–14
post-stroke; Sigma, St. Louis, MO) to reveal cell
proliferation. Analyses of BrdU labeling were
focused at the neurogenic subventricular zone
(SVZ) and the non-neurogenic striatum. The ra-
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that NT-020 could indeed increase cell prolif-
eration in a neurogenic site. Although an in-
crease cell proliferation in SVZ could be used
as a reasonable index to support a mechanism
for NT-020-mediated neuroprotection, we fur-
ther tested this hypothesis by subsequently an-
alyzing BrdU labeling in the ischemic striatum
to reveal whether newly formed cells from the
SVZ are able to migrate towards the site of in-
jury. This migration potential would reveal to
us stronger evidence of NT-020’s therapeutic
efficacy as such data demonstrate the com-
pound’s potential to not only increase cell pro-
liferation, but also to facilitate proper homing
of newly formed cells to the appropriate in-
jured brain site.
Neuronal differentiation assay
In the same vein of determining functionality
of cell proliferation and migration, we further
pursued characterizing whether NT-020 en-
hancement of newly formed cells similarly leads
to increased expression of neuronal phenotypes.
We find such neural differentiation to be a much
more stringent marker than merely enhanced
cell proliferation and migration, which would
bolster our hypothesized mechanism of neuro-
genesis underlying NT-020 neuroprotection.
BrdU-labeled brain sections (i.e., ischemic striatal
penumbra), used for cell proliferation/migration
studies above, were double labeled with the neu-
ronal marker doublecortin or glial marker GFAP.
ELISA of neurogenic factors upregulated 
by NT-020
Accumulating evidence implicates trophic
factors, such as stem cell factor (SCF), brain-de-
rived glial cell line-derived neurotrophic factor
(GDNF), neurotrophic factor (BDNF), and vas-
cular endothelial growth factor (VEGF), as criti-
cal neurogenic factors.31–33 Thus, we measured
these molecules as possible neurotrophic factors
upregulated with NT-020 treatment. Equal
amounts of cortical and striatal tissue ho-
mogenates were collected for ELISA. Tissue
punches from the ischemic striatum and cortex,
as well as the contralateral intact striatum and
cortex, were used as brain sampling sites. To con-
trol for intra-rat variability, we used the rat brain
matrix to accurately target the same striatum and
cortex along the anteroposterior axis (i.e., the
third slice of 2 mm block). Thereafter, a 2 mm di-
ameter tissue punch (using a calibrated tissue
puncher; Harris Micro-Punch, Redding, CA) was
made immediately below the corpus callosum
(corresponding to the striatum) and a second 2
mm punch was made immediately above the
corpus callosum (corresponding to the cortex).
This was done bilaterally, giving four sampling
sites per animal. The levels of SCF, GDNF,
BDNF, and VEGF were determined using ELISA
kits according to the manufacturer’s protocols
(BDNF and GDNF, Promega, Madison, WI;
VEGF and SCF, R&D Systems, Inc., Minneapo-
lis, MN). These ELISA systems can detect a min-
imum of 31.2, 15.6, 7.8, and 31.2 pg/mL of SCF,
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FIG. 1. Neurologic (Bederson test) and motor (EBST)
evaluations prior to stroke surgery (pre-stroke) revealed
no detectable behavioral deficits between groups. At 14
days after stroke (post-stroke), while both groups exhib-
ited motor and neurologic deficits (vs. pre-stroke, *p  
0.05), the NT-020-treated rats exhibited significantly less
motor and neurologic deficits than the vehicle-treated rats
did (**p   0.05).GDNF, BDNF, and VEGF, respectively. Tripli-
cate runs for each assay were performed.
RESULTS
NT-020 lessens stroke-induced behavioral deficits
ANOVA revealed significant treatment ef-
fects in both Bederson (F3,26   81.65,  p  
0.0001) and EBST (F3,26   29.26,  p   0.0001)
(Fig. 1). Pair-wise comparisons between treat-
ment groups using Fisher’s PLSD post-hoc t
tests revealed NT-020- and vehicle-treated
groups displayed no detectable behavioral im-
pairments at pre-stroke testing, but both ex-
hibited neurologic and motor deficits at post-
stroke testing (compared to pre-stroke, p  
0.05). However, NT-020-treated stroke animals
showed significantly less abnormalities in both
neurologic and motor tests compared to vehi-
cle-treated stroke animals (at post-stroke test-
ing, p   0.05). Reductions of 24.4% and 11.8%
in Bederson neurologic dysfunction and EBST
motor asymmetry, respectively, were detected
in NT-020-treated stroke animals compared to
vehicle-treated stroke animals. These results in-
dicate that pre-stroke treatment with NT-020
significantly ameliorated stroke-induced neu-
rologic and motor abnormalities.
NT-020 reduces stroke-induced cerebral infarcts
Student t test revealed that NT-020 reduced
the glial scar/ischemic area damage in the
striatum (Fig. 2a) compared to vehicle treat-
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FIG. 2. GFAP immunostaining was used to reveal glial scar. (a) Calculation of glial scar area using the formula C  
D/(A   B), with total hemisphere area (A), lateral ventricle (B), glial scar (C), and penumbra (D). NT-020 treatment
(a) significantly reduced the glial scar compared to vehicle treatment (b), as quantified in c (*p   0.0005).ment (Fig. 2b). A significant 75% decrement in
mean glial scar area was observed in the isch-
emic striatum of NT-020-treated stroke animals
compared to that of vehicle-treated stroke ani-
mals (p   0.0005) (Fig. 2c). These histological
results parallel the behavioral performance of
NT-020-treated stroke animals, suggesting that
a reduction in the extent of cerebral infarction
translated to attenuation of stroke-induced
functional deficits.
NT-020 promotes endogenous birth of 
new neurons
Immunofluorescence microscopy revealed
NT-020 (Fig. 3D-F) enhanced cell proliferation
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FIG. 3. BrdU labeling of brains from vehicle-(A-C) and NT-020-treated (D-F) stroke animals. NT-020 increased the
number of BrdU-positive proliferating cells in SVZ (D in rectangle, magnified in E) and ischemic striatum (D in cir-
cle, magnified in F) compared to vehicle treatment (SVZ, A in rectangle, magnified in B; striatum, A in circle, mag-
nified in C).DIET SUPPLEMENTATION PROTECTS AGAINST STROKE 207
FIG. 4. Quantitative analysis of BrdU labeling in SVZ
(A) followed the protocol by Baldauf and Reymann.47
Four rectangular sections (200  m   60  m) at 100  mag-
nification from two serial brain sections from each rat
were used to reveal mean BrdU cell counts along the SVZ.
For quantitative analysis of BrdU labeling in striatum, two
serial brain sections from each rat capturing the striatal
penumbra depicted in Figure 5A and D (and magnified
in Fig. 5Cand E), with each section corresponding to 40
 m   40  m, were used to reveal mean BrdU cell counts
in the ischemic striatum. Results revealed one-fold and
three-fold increments, respectively, in the SVZ (B) and
striatum  (C) of the NT-020-treated stroke brains com-
pared to vehicle-treated stroke brains (*p   0.0005 in SVZ
and *p   0.0001 in striatum when comparing corre-
sponding ischemic SVZs and striata between treatment
groups).
in SVZ and ischemic striatum characterized by
significantly increased BrdU labeling in these
brain sites compared to that of vehicle-treated
stroke brains (Fig. 3A-C). Quantitative analysis
of SVZ’s cell proliferative activity (Fig. 4A) re-
vealed significant treatment effects (F3,16  
8.03, p   0.0001), with at least a one-fold incre-
ment in the number of BrdU-positive cells in
the NT-020-treated stroke brains compared to
that of vehicle-treated stroke brains (p  
0.0005) (Fig. 3A, B, D, and E, with quantitative
data shown in Fig. 4B). Similarly, quantitative
analysis of BrdU labeling in the ischemic stri-
atal penumbra revealed significant treatment
effects (F3,16   11.84, p   0.0001), with at least
a 3-fold increase in the number of BrdU-posi-
tive cells in the NT-020-treated stroke brains
compared to vehicle-treated stroke brains (p  
0.0001) (Fig. 3A, C, D, and F, with quantitative
data shown in Fig. 4C). In contrast, when eval-
uation of BrdU labeling targeted the ischemic
core (instead of the penumbra, Fig. 3A and D),
there was a massive proliferation of BrdU-pos-
itive cells in the vehicle-treated stroke brains
compared to NT-020-treated stroke brains. This
obvious increment in BrdU core is not surpris-
ing as it has been established that BrdU labels
infiltrating reactive microglia, as well as de-
generating or dead cells, which are abundant
in the necrotic core.28,34–36Since NT-020-treated
stroke brains have smaller ischemic core, it is
expected that BrdU labeling in this region isless than that of the vehicle-treated stroke
brains. Accordingly, examination of cell prolif-
eration in the ischemic core presents as an ar-
tifact and may not truly reflect the neuropro-
tective BrdU labeling index. With this in mind,
we limited the evaluation of cell proliferation
to SVZ and ischemic penumbra. Both these sets
of data indicate that NT-020 increases cell pro-
liferation in the neurogenic SVZ and also facil-
itates the migration of several of these newly
formed cells towards the ischemic striatal
penumbra.
NT-020 facilitates neuronal phenotype 
expression of newly formed cells
Immunofluorescence microscopy revealed
widespread double labeling of cells with
BrdU and doublecortin in NT-020-treated
stroke brains, whereas only a few cells dou-
ble labeled with both BrdU and doublecortin
in vehicle-treated stroke brains (Fig. 5). Quan-
titative analysis revealed about 17% and 75%
double-labeling of BrdU and doublecortin in
respective intact and ischemic side of NT-020-
treated stroke brains, which were signifi-
cantly higher than those seen in the intact
(5%) and ischemic side (13%) of vehicle-
treated stroke brains (*p   0.05, **p   0.0001)
(Fig. 6, 7A). In contrast, only a few cells in
NT-020-treated stroke brains double labeled
with BrdU and GFAP, while many cells in ve-
hicle-treated stroke brains double labeled
with BrdU and GFAP (Fig. 6). Quantitative
analysis revealed about 1% and 2% double la-
beling of BrdU and GFAP in respective intact
and ischemic side of NT-020-treated stroke
brains, which were significantly lower than
those seen in the intact (18%) and ischemic
side (35%) of vehicle-treated stroke brains
(**p   0.0001) (Fig. 7B). These data indicate
that NT-020 induces neural differentiation,
with increased tendency towards neuronal
over glial lineage.
NT-020 attenuates stroke-induced alterations 
in neurogenic factors
ELISA of brain tissue homogenates revealed
that the levels of SCF, GDNF, BDNF, and VEGF
in the ischemic cortex and striatum of vehicle-
treated stroke animals were significantly re-
duced to 40-50% of the corresponding intact
brain regions. In contrast, the levels of these
same trophic factors in the ischemic cortex and
striatum of NT-020-treated stroke animals were
maintained to 70-80% of the corresponding in-
tact brain regions. Single ANOVAs for each
trophic factor assay revealed significant differ-
ences between the treatment groups (p  
0.0001), and post-hoc tests further confirmed
the neurogenic effects of NT-020 on the isch-
emic cortex and striatum compared to vehicle
treatment (*p   0.05 vs. corresponding brain
region from vehicle-treated stroke animals)
(Fig. 8).
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FIG. 5. NT-020 enhanced neuronal differentiation of newly formed cells in the ischemic striatum as revealed by a
high number of BrdU (D) and doublecortin (E) double-labeled cells (F) compared to vehicle treatment (A, BrdU; B,
doublecortin; C, merged).DISCUSSION
The present study demonstrates the robust
neuroprotective effects of NT-020 when given
prior to stroke. The observed amelioration of
stroke-induced behavioral deficits by NT-020
was accompanied by increased cell prolifera-
tion and neuronal differentiation of newly
formed cells in the stroke brain.
Diet supplementation in ischemic injury
Wang and colleagues22  recently demon-
strated the neuroprotective effects of diet sup-
plementation in focal ischemic brain. In this
study, they fed adult male Sprague-Dawley
rats with equal amounts of diets (blueberry,
spinach, or spirulina) or with control diet over
a 4-week period, and thereafter subjected the
animals to stroke surgery involving transient
ligation of the middle cerebral artery (MCAl).
This MCAl stroke model produces consistent
cerebral infarction predominantly to the cortex.
Behavioral and histological assays at 24 and 48
h revealed that stroke animals that received
blueberry-, spinach-, or spirulina-enriched di-
ets displayed significant increase in locomotor
activity that coincided with reduction in the
volume of infarction in the cerebral cortex.
Analyses of physiological parameters revealed
no differences in blood biochemistry, blood
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FIG. 6. NT-020 did not enhance differentiation of newly formed cells into glial lineage in the ischemic striatum, as
revealed by a few cells with BrdU (D) and GFAP (E) double labeling (F). In contrast, there were several cells that
double labeled with BrdU and GFAP in the vehicle-treated ischemic striatum (A, BrdU; B, GFAP; C, merged).
FIG. 7. (A) Quantitative analysis revealed significantly
higher double labeling of BrdU and doublecortin in NT-
020 than vehicle-treated stroke brains (*p   0.05, **p  
0.0001). (B)In contrast, there was significantly lower BrdU
and GFAP double labeling in NT-020 than vehicle-treated
stroke brains (**p   0.0001).
A
BCO2, and electrolyte levels across groups, sug-
gesting that changes in physiological functions
did not contribute to the observed neuropro-
tection. In addition, stroke animals treated with
blueberry, spinach, or spirulina exhibited sig-
nificantly lower caspase-3 activity in the isch-
emic hemisphere. These data demonstrate that
diet supplementation with blueberry, spinach,
or spirulina attenuated stroke-induced cerebral
infarction and apoptosis and general locomo-
tor impairments, and parallel similar neuro-
protective effects of diet supplementation seen
in other age-related disorders, such as Alzhei-
mer’s disease37 and Parkinson’s disease.38
However, until now the exact mechanism un-
derlying such neuroprotection remained to be
determined.
Diet supplementation and neurogenesis
Here, we demonstrate that NT-020 facilitated
endogenous neurogenesis in the stroke brain.
The mechanism underlying such enhanced
neurogenesis likely involves NT-020 upregu-
lating a myriad of endogenous neurogenic fac-
tors, including SCF, BDNF, GDNF and VEGF,
which in turn stimulate the birth of new neu-
rons in the ischemic brain. Previous studies
have implicated neurogenesis as a potent
neuroprotective pathway triggered by diet
supplementation. For example, short-term sup-
plementation with blueberry (one of the
components of NT-020) has been shown to in-
crease hippocampal neurogenesis,39 which
could account for the improvement of cogni-
tive function of aged animals treated with this
diet.37
The reverse diet manipulation paradigm in-
volving caloric restriction and intermittent
fasting has also been found to protect against
stroke.5,10,11 In these studies, rodent main-
tained on a caloric restriction diet or inter-
mittently fasted developed an increased re-
sistance of brain cells to experimental models
of stroke. Postulated mechanisms underlying
the neuroprotection produced by restricted
diet intake include decreased oxidative stress
and increased cellular stress resistance, which
singly or in combination can promote a “pre-
conditioning” state, priming the brain to
withstand a stroke insult. Additionally, up-
regulation of neurotrophic factor (i.e., in-
creased BDNF levels) signaling pathways has
been observed.11 Furthermore, these authors
noted that diet restriction can stimulate neu-
rogenesis and enhance synaptic plasticity.10,40
Clearly, the studies by Mattson and col-
leagues5,10,11,40 indicate that a regimen of re-
duced food intake exerts neuroprotection
against stroke.
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FIG. 8. ELISA revealed NT-020 treatment maintained 70-80% levels of trophic factors in the ischemic cortex and
striatum (*p   0.05 vs. corresponding brain region from vehicle-treated stroke animals).These past reports and our current data,
when taken together, support our general hy-
pothesis that diet manipulation, either by re-
stricting high caloric intake or via supplemen-
tation of nutritive diet extracts/compounds,
stands as an efficacious stroke adjunct therapy.
The present study provided direct evidence
that neurogenesis, implicated as a mechanism
underlying neuroprotective effects of diet re-
striction,40 similarly plays a major role in the
functional benefits of diet supplementation. In
view of the pathological manifestation of
stroke, at least in this MCAo model, character-
ized by extensive neuronal loss accompanied
by increased glial cell activation, it appears that
neuronal replacement will be more advanta-
geous than glial cell replenishment. The robust
neuronal differentiation at 2 weeks post-stroke
is equally beneficial since a rapid cell death cas-
cade proceeds after the stroke onset. Thus, the
preferential neuronal differentiation by newly
formed cells in the ischemic brain provides a
solid mechanistic pathway by which NT-020
renders neuroprotection in stroke.
Nutritive diet and oxidative stress
An equally important pathway for neuro-
protection by nutritive diet is the suppression
of oxidative stress. Indeed, a bulk of laboratory
evidence implicates the robust antioxidative
and chelating polyphenol effects20 of blueber-
ries,12,13 green tea,14,15 vitamin D3,16,17 and
carnosine.18,19These antioxidant features of nu-
tritive extracts, taken together with the ob-
served neurogenic potential, make these com-
pounds appealing as a class of neuroprotective
agents with multiple targets for arresting cell
death cascades. However, an ongoing contro-
versy is the ability of these compounds to tra-
verse the blood brain barrier (BBB) and afford
their effects in the CNS. In the diseased brain,
such as the present stroke, the BBB is shown to
be compromised,41,42 which could facilitate the
entry of these compounds to the brain. Alter-
natively, the development of small molecule
derivatives of these nutritive compounds that
could easily permeate across the BBB should
improve the CNS bioavailability and thera-
peutic benefits of NT-020.
Towards a multi-agent nutritive diet for stroke
Recent studies have demonstrated that some
of the agents we used in the present study are
neuroprotective against stroke22,43–46 and that
blueberry has been shown to increase neuro-
genesis.39 Based on these recent publications
under the major umbrella theme of plant ex-
tracts (specifically blueberry) and neuropro-
tection, the present study at first glance ap-
pears lacking in novelty. Despite these recent
publications with overlapping observations to
our study, the reports to date on nutritive
agents implicating their neuroprotective effects
against stroke have used a single agent ther-
apy. Accordingly, for such single agent treat-
ment regimen to render a therapeutic outcome,
the dosage of each agent is obviously higher
than the present multi-agent combination reg-
imen. We wish to advance the notion that this
agent dosage is critical for practical purposes,
especially when translating this potential treat-
ment to the clinic. In order to achieve neuro-
protection against stroke with a single agent
treatment regimen, one must load the patient
with high doses of each agent. However, in or-
der for the multi-agent combination regimen to
afford neuroprotection, the present study pro-
poses a modest and tolerable agent dosage (i.e.,
at least 20 times less of the dosage required for
the single agent regimen21,22). Equipped with
this new translational medicine information,
the present results provide a critical advance in
the scientific and clinical arena by demonstrat-
ing the advantage of multi-agent over single
agent regimen. In addition, a careful examina-
tion of the published study on the role of blue-
berry on neurogenesis39 reveals that blueberry
treatment (again as a single agent) in aged an-
imals enhanced hippocampal neuronal plastic-
ity, which correlates with improvements in
spatial memory. Although redundancies and
overlapping pathologic conditions exist in “ag-
ing” and “stroke” cell death pathways, inves-
tigations on the specific human disorder (in our
case, stroke) is necessary to either support or
detract from the proposed “neurogenic” po-
tential of blueberry. Thus, the present study
provides the first direct evidence of neurogenic
potential of nutritive diet (blueberry included)
DIET SUPPLEMENTATION PROTECTS AGAINST STROKE 211in stroke animals, which parallels the neuro-
protective mechanism of such compounds seen
in aged animals.
CONCLUSIONS
The present results highlight the functional
benefits of diet supplementation in enhancing
neurogenesis in the adult stroke brain. The im-
proved outcome in stroke animals exposed to
diet supplementation complements the exist-
ing reverse paradigm of diet restriction5,10,11,40
as a neuroprotective strategy. Furthermore, 
we identified that endogenous neurogenesis
closely accompanies diet supplementation as
seen with diet restriction, thereby advancing
the concept of enhancing the neurogenic po-
tential of the injured brain as a powerful strat-
egy in promoting neuroprotection against
stroke.
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